A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects

This clinical study will adopt a randomized, open-label, single-dose, 3-cycle, 3-way crossover design to explore the PK and PD profiles of a single oral dose of vicagrel capsules under fasted and fed conditions in health subjects.

Study Overview

• Status: Completed
• Conditions: Acute Coronary Syndrome
• Intervention / Treatment: Drug: vicagrel

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130000
      • The First hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Voluntary signing of informed consent before the trial, and full understanding of the experimental content, process and possible ARs;
• Able to complete the study according to the protocol;
• Subjects (and their partners) are willing to take effective contraceptive measures from screening to 6 month after the last dose of the IMPs. See Appendix 5 for specific contraceptive measures;
• Male and female subjects aged 18 to 45 years (inclusive);
• Male weight ≥50 kg, female weight ≥ 45 kg. Body mass index (BMI) = body weight (kg) / height2 (m2). BMI ranging from 18 to 28 kg/m2 (including critical values);
• Physical examination and vital signs are normal or abnormal without clinical significance.

Exclusion Criteria:

• More than 5 cigarettes per day on average 3 months before the trial;
• Allergic constitution (allergic to multiple drugs and foods), or known to be possibly allergic to drugs of the same class of the IMP or highly sensitive to clopidogrel;
• History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or use of hard drug within the past five years;
• Blood donation or massive blood loss (>450 mL) within 3 months before screening;
• Presence of dysphagia or history of any gastrointestinal and hepatic, renal disease (whether cured or not) or history of surgery that affects absorption or excretion of the IMP within 6 months prior to screening;
• With any disease that increases the risk of bleeding, such as acute gastritis, stomach and duodenal ulcers, or history of abnormal bleeding (e.g. bleeding time prolonged after tooth extraction);
• The subject or his or her immediate family member has a family history of coagulation or haemorrhagic disorders (such as haemophilia)/symptoms (such as hematemesis, melena, severe or recurrent epistaxis, coughing blood (hemoptysis), obvious hematuria or intracranial hemorrhage), or suspected vascular malformation, such as aneurysm or early-onset stroke;
• Took potent inhibitors and/or inducers of CYP enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days prior to the first dose. Potent inhibitors of CYP enzymes include ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc.. Potent inducers of CYP enzymes include rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc.. See Appendix 6 for details;
• Took any prescription, non-prescription, any vitamin or herbal drugs within 14 days before the first dose;
• Had foods that affect CYP3A4 metabolism within 2 weeks prior to the first dose, such as grapefruit or grapefruit-containing beverages, or had intense physical exercise (e.g. strength training, aerobic training, and playing football) within 7 days prior to the first dose, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
• Recently there have been major changes in diet or exercise habits;
• Participated in a another clinical study within 3 months prior to screening (a subject may be enrolled if he/she withdraws from the study prior to treatment, i.e., the subject is not randomized or doesn't receive treatment);
• Failure to tolerate high-fat meals (two boiled eggs, one slice of toast with butter and bacon, a box of French fries, a glass of whole milk);
• 12-lead ECG abnormalities have clinical significance;
• Female subjects who are in lactation or positive for serum pregnancy test in the screening period or during the trial;
• Clinical laboratory abnormalities have clinical significance or other clinically significant diseases before screening (including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, and lung, immune, mental or cardiovascular and cerebrovascular diseases);
• Positive for viral hepatitis (including hepatitis B and C), HIV antibody and treponema pallidum antibody during screening;
• Any acute diseases or concomitant medicines from screening period to before taking the IMPs;
• Took chocolate, any food or drink with caffeine or xanthine within 24 hours before the first dose;
• Took any alcoholic product or alcohol breath test is positive within 24 hours before the first dose;
• Urine drug screening positive;
• The investigator believes that there are other factors that are not suitable for participating in the trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: KGD; Oral administration after fasting/high-fat meal/low-fat meal	Drug: vicagrel; Oral administration after fasting/high-fat meal/low-fat meal
Experimental: GDK; Oral administration after high-fat meal/low-fat meal/fasting	Drug: vicagrel; Oral administration after fasting/high-fat meal/low-fat meal
Experimental: DKG; Oral administration after low-fat meal/fasting/high-fat meal	Drug: vicagrel; Oral administration after fasting/high-fat meal/low-fat meal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC	Area Under the Curve From Time Zero to Last Quantifiable Concentration	48 hours
Cmax	Peak concentration	48 hours

Collaborators and Investigators

• Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Study record dates

Study Major Dates

• Study Start (Actual): August 24, 2021
• Primary Completion (Actual): October 20, 2021
• Study Completion (Actual): October 20, 2021

Study Registration Dates

• First Submitted: June 8, 2021
• First Submitted That Met QC Criteria: June 8, 2021
• First Posted (Actual): June 9, 2021

Study Record Updates

• Last Update Posted (Actual): November 1, 2021
• Last Update Submitted That Met QC Criteria: October 25, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Acute Coronary Syndrome
• Other Study ID Numbers: VCP1-Ⅰ-05

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No